Pacific Shuanglin Bio-pharmacy Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
Pacific Shuanglin Bio-pharmacy Co., Ltd. carries a market capitalization of 9.22B, placing it among publicly traded companies globally. Its enterprise value stands at 14.94B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 9.22B |
| Enterprise Value | 14.94B |
Share Statistics
Pacific Shuanglin Bio-pharmacy Co., Ltd. currently has 950.40M shares outstanding.
| Shares Outstanding | 950.40M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Pacific Shuanglin Bio-pharmacy Co., Ltd. trades at a trailing price-to-earnings ratio of 64.12. The price-to-sales ratio is 7.55, and the price-to-book ratio stands at 4.38.
| PE Ratio | 64.12 |
| PS Ratio | 7.55 |
| PB Ratio | 4.38 |
| P/TBV Ratio | 2.86 |
| P/FCF Ratio | 74.06 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Pacific Shuanglin Bio-pharmacy Co., Ltd. trades at an EV/EBITDA multiple of 39.30 and an EV/FCF ratio of 69.04. The EV/Sales ratio of 7.59 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 39.30 provides insight into valuation relative to core operating earnings.
| EV / Sales | 7.59 |
| EV / EBITDA | 39.30 |
| EV / EBIT | 39.30 |
| EV / FCF | 69.04 |
Financial Position
Pacific Shuanglin Bio-pharmacy Co., Ltd. maintains a current ratio of 3.37, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.71, indicating elevated leverage, while an interest coverage ratio of 19.41 demonstrates strong ability to service its debt obligations.
| Current Ratio | 3.37 |
| Quick Ratio | 0.66 |
| Debt / Equity | 9.71 |
| Debt / EBITDA | 2.07 |
| Interest Coverage | 19.41 |
Financial Efficiency
Pacific Shuanglin Bio-pharmacy Co., Ltd. posts a return on equity of 7.14 and a return on invested capital of 3.47.
| Return on Equity (ROE) | 7.14 |
| Return on Assets (ROA) | 2.49 |
| Return on Invested Capital (ROIC) | 3.47 |
| Return on Capital Employed (ROCE) | 6.25 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.75 |
Taxes
Over the trailing twelve months, Pacific Shuanglin Bio-pharmacy Co., Ltd. has paid 56.26M in income taxes, reflecting an effective tax rate of 19.53.
| Income Tax | 56.26M |
| Effective Tax Rate | 19.53 |
Stock Price Statistics
Pacific Shuanglin Bio-pharmacy Co., Ltd.'s stock has declined approximately -46.49752% over the past 52 weeks. The 50-day moving average sits at 11.37, while the 200-day moving average is 13.66.
| Beta (5Y) | N/A |
| 52-Week Price Change | -46.49752% |
| 50-Day Moving Average | 11.37 |
| 200-Day Moving Average | 13.66 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Pacific Shuanglin Bio-pharmacy Co., Ltd. generated 1.97B in revenue and converted that into 231.76M in net income, yielding earnings per share of 0.20. EBITDA reached 380.21M, while operating income came in at 380.21M.
| Revenue | 1.97B |
| Gross Profit | 753.14M |
| Operating Income | 380.21M |
| Pretax Income | 288.01M |
| Net Income | 231.76M |
| EBITDA | 380.21M |
| EBIT | 380.21M |
| Earnings Per Share (EPS) | 0.20 |
Balance Sheet
Pacific Shuanglin Bio-pharmacy Co., Ltd. holds 699.24M in cash and equivalents against 787.09M in total debt, resulting in a net debt position of 262.63M. Total book value stands at 3.39B, with working capital of 2.50B providing operational flexibility.
| Cash & Cash Equivalents | 699.24M |
| Total Debt | 787.09M |
| Net Debt | 262.63M |
| Equity (Book Value) | 3.39B |
| Book Value Per Share | 2.96 |
| Working Capital | 2.50B |
Cash Flow
After subtracting -200.66M in capital expenditures, free cash flow totaled -200.66M - equivalent to -0.17 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -200.66M |
| Free Cash Flow | -200.66M |
| FCF Per Share | -0.17 |
Margins
Pacific Shuanglin Bio-pharmacy Co., Ltd. operates with a gross margin of 38.25, reflecting its pricing power and cost economics. The operating margin of 19.31 and net profit margin of 11.77 provide insight into operational efficiency.
| Gross Margin | 38.25 |
| Operating Margin | 19.31 |
| Pretax Margin | 14.63 |
| Profit Margin | 11.77 |
| EBITDA Margin | 19.31 |
Dividends & Yields
The company's payout ratio of 116.14 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.23 |
| Dividend Yield | N/A |
| Payout Ratio | 116.14 |
| Shareholder Yield | 2.05 |
| FCF Yield | 1.35 |
Stock Splits
Pacific Shuanglin Bio-pharmacy Co., Ltd.'s most recent stock split took place on July 27, 2020 with a 1000000:1952679 split ratio.
| Last Split Date | 7/27/2020 |
| Split Ratio | 1000000:1952679 |
Scores
Pacific Shuanglin Bio-pharmacy Co., Ltd. posts an Altman Z-Score of 8.46, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 8.46 |